<DOC>
	<DOCNO>NCT00307593</DOCNO>
	<brief_summary>The purpose study compare 2 immunosuppressant regimen treatment relapse refractory necrotizing antineutrophil cytoplasmic antibody ( ANCA ) associate vasculitides .</brief_summary>
	<brief_title>RATTRAP : Infliximab Versus Rituximab Systemic Necrotizing Vasculitides</brief_title>
	<detailed_description>The aim study compare efficacy rituximab versus infliximab relapse refractory form ANCA+ vasculitides ( Microscopic Polyangiitis , Wegener 's granulomatosis Churg-Strauss syndrome ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Systemic ANCA positive ( + ) vasculitides Relapsing refractory vasculitides , resistant corticosteroid reference immunosuppressant therapy Age &gt; 18 year old Written inform consent Newly diagnose patient Patient never receive immunosuppressant treat his/her vasculitis Malignancy Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Systemic ANCA+ vascularizes</keyword>
	<keyword>Relapse</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Immunosuppressant</keyword>
	<keyword>Infliximab/rituximab</keyword>
	<keyword>Patients relapse refractory form ANCA</keyword>
	<keyword>associate vasculitides Microscopic polyangiitis</keyword>
</DOC>